COVID antibody drugs have saved lives — so why aren’t they more popular?

Asher Mullard

Nature, 2022, vol. 606, issue 7916, 854-856

Abstract: Drugs made from antibodies are huge money-makers for some conditions — but they have gained little traction in infectious diseases, including COVID.

Keywords: Drug discovery; SARS-CoV-2; Immunology (search for similar items in EconPapers)
Date: 2022
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/d41586-022-01735-7 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:606:y:2022:i:7916:d:10.1038_d41586-022-01735-7

Ordering information: This journal article can be ordered from
https://www.nature.com/

DOI: 10.1038/d41586-022-01735-7

Access Statistics for this article

Nature is currently edited by Magdalena Skipper

More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().